Novel approaches to imatinib-and sunitinib-resistant GIST

Current Oncology Reports

Volumn 10, Issue 4, 2008, Pages 344-349

  Reichardt, Peter ^a  

^a HELIOS Klinikum Bad Saarow   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BCR ABL PROTEIN; BEVACIZUMAB; CD135 ANTIGEN; CEDIRANIB; DASATINIB; DOXORUBICIN; EVEROLIMUS; FLAVOPIRIDOL; HEAT SHOCK PROTEIN 90; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MIDOSTAURIN; MOTESANIB; NILOTINIB; PERIFOSINE; PLACEBO; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SORAFENIB; STEM CELL FACTOR; SUNITINIB; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB; XL 820; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDEMA; ENZYME INHIBITION; EXON; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; MISSENSE MUTATION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PATIENT COMPLIANCE; REVIEW; SIDE EFFECT; SKIN EXFOLIATION; VOMITING; WEIGHT REDUCTION; DRUG ANTAGONISM; DRUG RESISTANCE; METABOLISM; PATHOLOGY;

ANGIOGENESIS INHIBITORS; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; PYRROLES;

EID: 56149126724     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-008-0053-4     Document Type: Review

References (28)

1. Corless CL, Fletcher JA, Heinrich MC: Biology of gastroin-testinal stromal tumors. J Clin Oncol 2004, 22:3813-3825.
2. Hirota S, Isozaki K, Moriyama Y, et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998, 279:577-580.
3. Heinrich MC, Corless CL, Demetri GD, et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21:4342-4349.
4. Debiec-Rychter M, Sciot R, Le Cesne A, et al.: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006, 42:1093-1103.
5. Tornillo L, Terracciano LM: An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 2006, 59:557-563.
6. Verweij J, Casali PG, Zalcberg J, et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004, 364:1127-1134.
7. Blanke CD, Demetri GD, von Mehren M, et al.: Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008, 26:620-625.
8. Blanke CD, Rankin C, Demetri GD, et al.: Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008, 26:626-632.
9. Van Glabbeke MM, Owzar K, Rankin C, et al.: Comparison of two doses of imatinib for the treatment of gastro-intestinal stromal tumors (GIST): A meta-analysis based on 1640 patients [ASCO abstract 10004]. J Clin Oncol 2007, 25(18S):10004.
10. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
11. Heinrich MC, Corless CL, Blanke CD, et al.: Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006, 24:4764-4774.
12. Demetri GD, van Oosterom AT, Garrett CR, et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006, 368:1329-1338.
13. Benjamin RS, Schoffski P, Hartmann JT, et al.: Initial results of a multicenter single arm phase 2 study of AMG 706, an oral multikinase inhibitor, for the treatment of advanced imatinib-resistant gastrointestinal stromal tumors (GIST) [abstract 641]. Presented at the 12th Annual Meeting of the Connective Tissue Oncology Society; November 2-4, 2006; Venice, Italy.
14. Yamada Y, Sawaki A, Nishida T, et al.: Phase II study of motesanib diphosphonate (AMG 706) in Japanese patients with advanced gastrointestinal stromal tumors (GIST) who developed progressive disease or relapsed while on imatinib mesylate [abstract]. Presented at the 2008 ASCO Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL. Abstract 107.
15. Joensuu H, De Braud F, Coco P, et al.: Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 2008, 19:173-177.
16. Weisberg E, Manley PW, Breitenstein W, et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005, 7:129-141.
17. Prenen H, Guetens G, de Boeck G, et al.: Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines. Pharmacology 2006, 77:11-16.
18. Roberts KG, Odell AF, Byrnes EM, et al.: Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 2007, 6:1159-1166.
19. von Mehren M, Reichardt P, Casali PG, et al.: A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update [ASCO abstract 10023]. J Clin Oncol 2007, 25(18S):10023.
20. Schittenhelm MM, Shiraga S, Schroeder A, et al.: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006, 66:473-481.
21. Evans TR, Morgan JA, van den Abbeele AD, et al.: Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients with GIST and other solid tumors [ASCO abstract 3034]. J Clin Oncol 2005, 23(16S):3034.
22. Nimeiri HS, Maki RG, Kasza K, et al.: Activity of sorafenib in patients with imatinib and sunitinib-resistant gastrointestinal stromal tumors: A phase II trial of the University of Chicago Phase II Consortium [abstract 7]. Presented at the 2008 ASCO Gastrointestinal Cancers Symposium; January 25-27, 2008; Orlando, FL.
23. Debiec-Rychter M, Cools J, Dumez H, et al.: Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005, 128:270-279.
24. Reichardt P, Pink D, Lindner T, et al.: A phase I/II trial of the oral PKC-inhibitor PKC412 in combination with imatinib mesylate in patients with gastrointestinal stromal tumor (GIST) refractory to IM [ASCO abstract 3016]. J Clin Oncol 2005, 23(16S):3016.
25. Van Oosterom A, Reichardt P, Blay JY, et al.: A phase I/II trial of the oral mTOR-inhibitor everolimus and imatinib mesylate in patients with gastrointestinal stromal tumor (GIST) refractory to IM: Study update [ASCO abstract 9033]. J Clin Oncol 2005, 23(16S):9033.
26. Bauer S, Yu LK, Demetri GD, Fletcher JA: Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006, 66:9153-9161.
27. Demetri GD, George S, Morgan JA, et al.: Inhibition of the heat shock protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors in metastatic GIST: Updated results of a phase I trial [ASCO abstract 10024]. J Clin Oncol 2007, 25(18S):10024.
28. Sambol EB, Ambrosini G, Geha RC, et al.: Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res 2006, 66:5858-5866.